Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13503036 | 1.00 | MAPT (0.47) | MAPTHTTHPGDCYP1A2CYP2C19 | |
| SCHEMBL504040 | 0.80 | SMN1; SMN2 (0.53) | MAPTHTTHPGDCYP1A2CYP2C19 | |
| SCHEMBL12778132 | 0.80 | SMN1; SMN2 (0.53) | MAPTHTTHPGDCYP1A2CYP2C19 | |
| SCHEMBL504041 | 0.80 | SMN1; SMN2 (0.53) | MAPTHTTHPGDCYP1A2CYP2C19 | |
| SCHEMBL31145321 | 0.74 | ALDH1A1 (0.49) | MAPTHTTHPGDCYP1A2CYP2C19 | |
| SCHEMBL8681876 | 0.74 | HTT (0.57) | MAPTHTTHPGDCYP1A2CYP2C19 | |
| SCHEMBL8681874 | 0.74 | HTT (0.57) | MAPTHTTHPGDCYP1A2CYP2C19 | |
| SCHEMBL581067 | 0.73 | SMN1; SMN2 (0.55) | MAPTALDH1A1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL3656546 | 0.73 | LMNA (0.41) | ALDH1A1KDM4ESMN1; SMN2POLBLMNA | |
| SCHEMBL1119080 | 0.73 | SMN1; SMN2 (0.41) | MAPTHTTHPGDALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| EP-2094682-A2 | HETEROARYL-HETEROARYL COMPOUNDS AS CDK INHIBITORS FOR THE TREATMENT OF CANCER, INFLAMMATION AND VIRAL INFECTIONS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008079933-A2 | HETEROARYL-HETEROARYL COMPOUNDS AS CDK INHIBITORS FOR THE TREATMENT OF CANCER, INFLAMMATION AND VIRAL INFECTIONS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048597-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | MAPT 1424/4885HTT 961/4885HPGD 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.